Volume 3.06 | Feb 14

Hematopoiesis News 3.06, February 14, 2012
Hematopoiesis News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
The Combination of Valproic Acid and Lithium Delays Hematopoietic Stem/Progenitor Cell Differentiation
Results demonstrate that the combination of valproic acid and lithium potently delays differentiation at the biological and the molecular level, and provide evidence to suggest that combinatorial screening of chemical compounds may uncover possible additive/synergistic effects to modulate stem cell fate decisions. [Blood] Abstract

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors
PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
Researchers show that the NAD+-dependent deacetylase SIRT1 is overexpressed in human chronic myelogenous leukemia (CML) stem cells. [Cancer Cell] Abstract | Press Release

N-Cadherin in Osteolineage Cells Is Not Required for Maintenance of Hematopoietic Stem Cells
There is evidence suggesting that N-cadherin expression on osteoblast lineage cells regulates hematopoietic stem cell function and quiescence. To test this hypothesis, scientists conditionally deleted N-cadherin (Cdh2) in osteoblasts using Cdh2flox/flox Osx-Cre mice. [Blood] Abstract

F Box Protein FBXL2 Targets Cyclin D2 for Ubiquitination and Degradation to Inhibit Leukemic Cell Proliferation
Investigators describe the behavior of a relatively new SCF (Skip-Cullin1-F-box protein) subunit, termed FBXL2, that ubiquitinates and destabilizes cyclin D2 protein leading to G0 phase arrest and apoptosis in leukemic and B lymphoblastoid cell lines. [Blood] Abstract

Knock-In of a FLT3/ITD Mutation Cooperates with a NUP98-HOXD13 Fusion to Generate Acute Myeloid Leukemia in a Mouse Model
Previous work has shown that insertion of a FLT3/ internal tandem duplication (ITD) mutation into the murine Flt3 gene induces a myeloproliferative neoplasm, but not progression to acute leukemia, suggesting that additional cooperating events are required. Scientists combined the FLT3/ITD mutation with a model of myelodysplastic syndrome involving transgenic expression of the Nup98-HoxD13 fusion gene. [Blood] Abstract

Molecular and Cellular Effects of Oncogene Cooperation in a Genetically Accurate AML Mouse Model
Investigators have generated an acute myeloid leukemia (AML) mouse model using knock-in mouse strains to study cooperation of internal tandem duplication mutation in the Flt3 gene with commonly observed C/EBPα mutations. [Leukemia] Abstract

Overexpression of Wild-Type or Mutants Forms of CEBPA Alter Normal Human Hematopoiesis
Data underline the critical role of C/EBPα (CEBPA) in human hematopoiesis and demonstrate that C/EBPα mutations (alone or in combination) are insufficient to convert normal human hematopoietic stem/progenitors into leukemic initiating cells, although individually each altered normal hematopoiesis. [Leukemia] Abstract

Dynamic Interaction Between TAL1 Oncoprotein and LSD1 Regulates TAL1 Function in Hematopoiesis and Leukemogenesis
Here, scientists reported that protein kinase A-mediated phosphorylation regulates TAL1 interaction with the lysine-specific demethylase (LSD1) that removes methyl group from methylated Lys 4 on histone H3 tails. [Oncogene] Abstract

CLINICAL RESEARCH

Early Matched Sibling Hematopoietic-Cell Transplantation for Adult AML in First Remission Using an Age-Adapted Strategy: Long-Term Results of a Prospective GOELAMS Study
The GOELAMS LAM2001 phase III trial, involving 832 patients with acute myeloid leukemia (AML) (median: 46 years, range: 17-60) proposed HLA-identical sibling allograft of hematopoietic stem cells for all patients with an identified donor. [Blood] Abstract

Outcomes After Matched Unrelated Donor vs. Identical Sibling Hematopoietic Cell Transplantation (HCT) in Adults with Acute Myelogenous Leukemia (AML)
Researchers analyzed outcomes of 2,223 adult AML patients who underwent allogeneic HCT between 2002 and 2006 (matched related donor, n=624; 8/8 human leukocyte antigen locus matched unrelated donor (MUD), n=1193; 7/8 MUD, n=406). [Blood] Abstract

ee Recommendations: Reducing Immunosuppression Testing By Using Customized Assays To Evaluate Myelotoxicity First
SCIENCE NEWS
Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
Bio-Path Holdings, Inc., announced that it has completed treatment of the second dosage cohort in the Company’s Phase I clinical trial of its lead product candidate, BP-100-1.01 (Liposomal Grb-2), which is a systemic treatment for blood cancers including acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome. [Bio-Path Holdings, Inc.] Press Release
INDUSTRY NEWS
Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia
Coronado Biosciences, Inc. announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for CNDO-109, a novel biologic that primes natural killer cells without the need for cytokines (IL-2), and is being studied for the treatment of patients with high risk acute myeloid leukemia in first complete remission. [Coronado Biosciences, Inc.] Press Release

Formula Pharmaceuticals Appoints Dr. Wolfgang Oster as Chairman, Board of Directors
Formula Pharmaceuticals announced the appointment of Wolfgang Oster, MD PhD as Chairman of the Board of Directors. [Formula Pharmaceuticals, Inc.] Press Release

Ambit Biosciences Appoints Athena Countouriotis as Chief Medical Officer
Ambit Biosciences announced the appointment of Athena Countouriotis, M.D., as chief medical officer. [Ambit Biosciences, Inc.] Press Release

Seattle Genetics Reports Fourth Quarter and Year 2011 Financial Results
Seattle Genetics, Inc. reported financial results for the fourth quarter and year ended December 31, 2011. The company also highlighted the ADCETRIS (brentuximab vedotin) product launch, recent ADCETRIS clinical data, ongoing and planned clinical development activities and upcoming milestones. [Seattle Genetics, Inc.] Press Release

Research Partnership to Improve Treatments for Cancer Patients
The Australian Cancer Research Foundation has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute. [Walter and Eliza Hall Institute] Press Release
POLICY NEWS

FDA Panel Rejects Eisai’s Leukemia Drug
An independent advisory panel to the U.S. health regulator said that Japanese drugmaker Eisai Co Ltd’s Dacogen did not show a favorable risk-benefit profile to treat a type of blood cancer. [U.S. Food and Drug Administration (FDA), United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW Cell Culture World Congress
February 28-March 1, 2012
Munich, Germany

Visit our events page to see a complete list of events in the hematopoietic community
JOB OPPORTUNITIES

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Researchers (Centre for Cancer Biology)

Postdoctoral/Research Associate (Children’s Memorial Research Center)

Pediatric Faculty – Hematology/Oncology Stem Cell Sciences (The University of Chicago)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us